
TSE:HHL
This summary was created by AI, based on 4 opinions in the last 12 months.
The Healthcare Leaders Income ETF (HHL-T) is positioned within a challenging U.S. healthcare sector that is experiencing pressure due to various factors, including public sentiment towards health insurance companies. This ETF holds around 20-23 large healthcare names on an equal-weight basis, with a significant portion in pharmaceuticals and healthcare equipment. While the management expense ratio (MER) is approximately 1%, making it somewhat pricey, the strategy of covered writing in the portfolio generates additional income, adding value for investors. Despite recent struggles, the ETF offers good diversification, especially for Canadian-centric portfolios. Experts suggest that this ETF could be part of a balanced strategy for both income and growth, particularly with favorable demographic trends despite the challenges presented by political factors and market volatility.
This invests in healthcare related securities, and believes the enhancement comes from an option strategy overlay. Like any other sector, this is fine when it is going up. This ETF tends to have a lot of volatility compared to some of the others. He doesn’t use this, so doesn’t know that much about it. It’s a fine product and he has no issues with it. It has a pretty significant yield, which tends to be what attracts a lot of people. Dividend yield of 8%+ right now.
A theme that he is very interested in. He doesn’t know what this REIT actually owns, but would assume you will have your pharmaceuticals, and hopefully the bio-technology space. Even if it doesn’t have bio-technology, you might want to look at having this in your portfolio, even at these levels. Yield is 7%, so he presumes they are writing covered calls against these positions.
The US healthcare bill having failed Friday puts some risk into the sector. He would be fine if it fell back to support levels, but would not step in today, otherwise it is a fine quality holding.